ANNEXON, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
ANNEXON, INC. (ANNX) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value of $4.73 per share as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-08-12
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $4.73.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $4.72.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $3.31.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value $3.30.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value |
|---|---|
| 2026-06-30 | $4.73 10-Q · filed 2026-08-12 |
| 2026-03-31 | $4.72 10-Q · filed 2026-05-07 |
| 2025-12-31 | $3.31 10-Q · filed 2026-08-12 |
| 2025-09-30 | $3.30 10-Q · filed 2025-11-10 |
| 2025-06-30 | $3.31 10-Q · filed 2025-08-14 |
| 2025-03-31 | $3.29 10-Q · filed 2025-05-12 |
| 2024-12-31 | $5.28 10-K · filed 2026-03-30 |
| 2024-09-30 | $5.35 10-Q · filed 2024-11-14 |
| 2024-06-30 | $5.24 10-Q · filed 2024-08-12 |
| 2024-03-31 | $5.24 10-Q · filed 2024-05-13 |
| 2023-12-31 | $5.69 10-K · filed 2025-03-03 |
| 2023-09-30 | $5.84 10-Q · filed 2023-11-13 |
| 2023-06-30 | $5.59 10-Q · filed 2023-08-07 |
| 2023-03-31 | $5.58 10-Q · filed 2023-05-08 |
| 2022-12-31 | $5.58 10-K · filed 2024-03-26 |
| 2022-09-30 | $5.76 10-Q · filed 2022-11-03 |
| 2022-06-30 | $7.75 10-Q · filed 2022-08-08 |
| 2022-03-31 | $7.81 10-Q · filed 2022-05-09 |
| 2021-12-31 | $12.84 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |